| 000 | 01706 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517100451.0 | ||
| 264 | 0 | _c20170731 | |
| 008 | 201707s 0 0 eng d | ||
| 022 | _a1099-1557 | ||
| 024 | 7 |
_a10.1002/pds.4045 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHuynh, Andrew Liem Hieu | |
| 245 | 0 | 0 |
_aDenosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting. _h[electronic resource] |
| 260 |
_bPharmacoepidemiology and drug safety _c11 2016 |
||
| 300 |
_a1274-1278 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 | _aAustralia |
| 650 | 0 | 4 |
_aBone Density Conservation Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aCalcium _xadministration & dosage |
| 650 | 0 | 4 |
_aCholecalciferol _xadministration & dosage |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aDenosumab _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGlomerular Filtration Rate |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypocalcemia _xchemically induced |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aRenal Insufficiency, Chronic _xcomplications |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aSex Factors |
| 650 | 0 | 4 | _aTertiary Care Centers |
| 650 | 0 | 4 |
_aVitamin D _xanalogs & derivatives |
| 700 | 1 | _aBaker, Scott Thomas | |
| 700 | 1 | _aStewardson, Andrew James | |
| 700 | 1 | _aJohnson, Douglas Forsyth | |
| 773 | 0 |
_tPharmacoepidemiology and drug safety _gvol. 25 _gno. 11 _gp. 1274-1278 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/pds.4045 _zAvailable from publisher's website |
| 999 |
_c26085557 _d26085557 |
||